Cyclopharm Limited · ASX:CYC
Cyclopharm — Australian Microcap Investment Conference 2016
28 slides from Cyclopharm's conference presentation, Oct 19, 2016
Slide 1: Cyclopharm Limited: A profitable and growing market leader
For personal use only Cyclopharm Limited A profitable and growing market leader in nuclear medical imaging and lung healthcare Australian Microcap Investment Conference 19 October 2016 1
Slide 2: Contents
For personal use only Contents James McBrayer, Managing Director • Company Overview • Cyclopharm’s Technology Overview • Financial Highlights • Product Overview and Growth Opportunities o Technegas o Ultralute™ • Strategic Priorities and Outlook 2
Slide 3: Investment Highlights
Investment Highlights For personal use only CYC is a leading player in the global nuclear medicine imaging and lung health markets • Technegas: Diagnosis & monitoring of lung diseases • UltraluteTM: Extends useful life of medical isotopes $ • 1H16 Sales: • 1H16 EPS: A$6.5 million 0.51 cents 27%
Slide 4: Our Strategy
Our Strategy For personal use only CYC has a clear strategy to leverage our position as a leading player in the global nuclear medicine imaging market and lung health space to expand the use of our proprietary products and introduce new innovative technology. We will do this by: 1. Attaining approva
Slide 5: CYC's Fast Facts
CYC’s 10 Fast Facts For personal use only 1. Technegas is a well established proprietary world leader in functional lung ventilation imaging technology with service and capital equipment revenue streams, the majority of sales generated from single patient consumables 2. Technegas is sold in 55 count
Slide 6: Our Technology: Business Model Based on Annuity Stream From Consumables
Our Technology…. Business Model Based on Annuity Stream From Consumables For personal use only Manufacturer and distributor • Invented in 1986 of pulmonary ventilation • Track record of growing revenue, imaging devices and profits and cash flows equipment • USFDA trials for sales in US progressing •
Slide 7: 1H 2016 Achievements
1H 2016 Achievements For personal use only • 1H 2016 Sales of $6.54 million • 1H 2016 EBIT $0.8 million • Payment of recurring dividends • Cash reserves at 30 June totalling $6.8 million after repayment of debt • USFDA clinical trial program commenced • Decision to move forward with the USA expansio
Slide 8: Technegas Half Year Results
Technegas Half Year Results For personal use only Record 1H Sales and Gross Margin Result Half Year ending 30 June ($000's) 1H 2016 1H 2015 1H 2014 1H 2013 • Record 1H Revenue Technegas Division Revenue 6,457 5,033 6,015 4,083 • Record 1H Gross Technegas Division Margin 5,386 3,969 4,608 3,037 Margi
Slide 9: Technegas Full Year Performance
Technegas Full Year Performance For personal use only Second consecutive year of record results • Another record financial result in FY15 Year ended 31 December ($000’s) 2015 Change 2014 Change 2013 • PAS margins enhanced by Technegas Results: improved local prices in Asia Sales Revenue and Latin Am
Slide 10: Group Balance Sheet
Cyclopharm Group Balance Sheet For personal use only Solid Financial Foundation to Leverage Growth Strategy • Improved cash position ($000’s) 1H 2016 FY 2015 FY 2014 driven by strong cash flows Cash 6,816 6,445 3,268 from operations Other current assets 6,168 6,653 5,582 Non-current Assets 3,389 3,4
Slide 11: Growth Drivers: Technegas – Expanding the Global footprint
Growth Drivers: Technegas – Expanding the Global footprint For personal use only • Technegas sold in 55 countries − Europe is the largest regional market for Technegas − In 2014 Canada became largest country market for Technegas, surpassing France • Over 3,500,000 patient studies since 1986 • 1,500
Slide 12: Technegas – USFDA clinical trial program on track
Technegas – USFDA clinical trial program…. ON TRACK For personal use only USA Market Size: • Half the world’s nuclear medicine departments are in the USA • USA represents a potential base Pulmonary Embolism market of 480,000 patients per annum. (Current Rest of the World volumes = 200,000 patients p
Slide 13: Technegas – The Canadian Case Study
Technegas – The Canadian Case Study For personal use only The Generator and Consumable Relationship • Canada is our largest single country market with 12 consecutive years of PAS growth • Canada represents a strong indicator of USA acceptance • Xe133 rapidly displaced by early adopters • Direct corr
Slide 14: Evolution of Functional Lung Ventilation Imaging
Evolution of Functional Lung Ventilation Imaging For personal use only • Improvements in 3D imaging techniques, hybrid imaging and the advent of analytical software have dramatically improved the sensitivity and specificity in functional lung imaging with Technegas • Traditionally used in the diagno
Slide 15: Technegas – Global Indication Expansion
Technegas – Global Indication Expansion For personal use only Targeting Chronic Obstructive Additional indication and applications Pulmonary Disease (COPD) market – Asthma, Lung Reduction and CTEPH* Evaluating the effectiveness of Technegas in Technegas can provide the clinician the ability to early
Slide 16: Indication expansion – Targeting COPD in China
Technegas Indication expansion – Targeting COPD in China For personal use only • The Global incidence of Chronic Obstructive Pulmonary Disease (COPD) is 30x greater than that of Pulmonary Embolism (PE) • By 2030 COPD is estimated to be world’s 3rd highest cause of death • Between 2003 and 2033, it i
Slide 17: Australian Pilot Clinical Trial to Commence
Expanding the use of Technegas Australian Pilot Clinical Trial to Commence For personal use only • Partnership with the University of Newcastle, John Hunter Hospital and Hunter Medical Research Institute • Targeting Clinical Applications in COPD Patients • Clinical Hypothesis: Small airway dysfuncti
Slide 18: Ultralute Product Overview
UltraluteTM For personal use only Product Overview Technology Features • Disruptive Technology – changes 60 years of • Enables a user to extend the usable life of how radiopharmaceuticals are manufactured a Mo99 Generator • Extends the effective use of Mo99 generator • Allows the user to purchase a
Slide 19: Ultralute Generation overview
UltraluteTM Generation overview For personal use only • Designed for the end user application • There are 4,000 Mo99 • Introduced to market Q4 2015 with revenues GEN 1 commencing 1H 2017 generators sold worldwide each week. • Designed for radiopharmacy application • Development will commence in 2017
Slide 20: Ultralute: Targeting direct users of Mo99
UltraluteTM Targeting direct users of Mo99 For personal use only • UltraluteTM v1 is targeted at the clinical end-user market that sources Mo99 Generators directly from manufacturers • The European Mo99 generator market is completely Direct • UltraluteTM registration in the EU has determined it to b
Slide 21: 2016 Strategic Priorities and Outlook
2016 Strategic Priorities and Outlook For personal use only Strategic Goals & Guidance Activity Timeframe United States • Proceeded on an independent path to USA market approval Q2 2016 FDA approval • USFDA clinical trial program commenced Q2 2016 • Relocate the Cyclopharm manufacturing premises and
Slide 22: Overview of Cyclopharm
Overview of Cyclopharm For personal use only Over the past 2 years, Cyclopharm has delivered a substantial increase in shareholder value through executing our strategy in the global manufacture and supply of innovative nuclear medicine technologies • Well established, profitable and fiscally discipl
Slide 23: Appendix Section
For personal use only Cyclopharm Limited Appendix Section • Cyclopharm History • MMI • Growth Opportunities and Key Performance Indicators • Disclaimer 23
Slide 24: Our History
Our History For personal use only 1984 1992 2000 2001 2007 2013 Technegas European markets Vita Life Sciences USFDA Technegas Plus UltraluteTM discovered and established acquires program initiated generator launched technology commercialised Tetley Medical for Technegas established 1985 1995 2000 20
Slide 25: Macquarie Medical Imaging
Macquarie Medical Imaging For personal use only • Joint venture with: • 50% Alfred Health Solutions CT MRI PET • 30% Macquarie University • 20% Cyclopharm • Comprehensive suite of imaging modalities • State of the art research platform • Growth and profitability linked to ramp-up Cardiac CT Ultra-so
Slide 26: Growth Opportunities and Key Performance Indicators: Technegas
Growth Opportunities and Key Performance Indicators For personal use only Technegas USA • The USA represents the single largest market with half of the world’s nuclear medicine departments located there • Existing market for PE in the USA equates to ~480,000 patients per annum • First priority follo
Slide 27: Growth Opportunities and Key Performance Indicators: Ultralute, MMI, Cyclopet
Growth Opportunities and Key Performance Indicators For personal use only Ultralute MMI Cyclopet Market • Europe targeted as the Revenue Volumes closely aligned with Molecular Following competition from Penetration primary market to launch the hospital. Continued double Imaging government owned ente
Slide 28: Disclaimer
For personal use only Disclaimer Corporate Head Office Certain views expressed here contain information derived from publicly available sources that have not Cyclopharm Limited been independently verified. Building 75 Business & Technology Park New Illawarra Road The presentation include certain sta
Cyclopharm — Australian Microcap Investment Conference 2016 on 6ix